alanine has been researched along with Stroke in 18 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 9.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| "Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a genetically heterogeneous disorder caused by mitochondrial DNA (mtDNA) mutations in the MT-TL1 gene." | 8.12 | Elevated glutamate and decreased glutamine levels in the cerebrospinal fluid of patients with MELAS syndrome. ( Arenas, J; Arranz-Canales, E; Delmiro, A; Domínguez-González, C; González de la Aleja, J; Guerrero-Molina, MP; Martín, MA; Morales-Conejo, M; Morán, M; Ramos-González, A, 2022) |
| "Sprague-Dawley rats were used in middle cerebral artery occlusion model of stroke." | 5.62 | Post Stroke Safinamide Treatment Attenuates Neurological Damage by Modulating Autophagy and Apoptosis in Experimental Model of Stroke in Rats. ( Dinda, AK; Joshi, B; Reeta, KH; Sharma, U; Singh, D; Wasan, H, 2021) |
| "Safinamide is a newly approved add-on drug to treat Parkinson's disease, and previously studies suggest safinamide could have a potential role on neuroprotection." | 5.56 | The Protective Effect of Safinamide in Ischemic Stroke Mice and a Brain Endothelial Cell Line. ( Kong, S; Sun, R; Wei, G; Xu, T, 2020) |
| " Orbofiban, despite no significant excess risk of ICH, was not effective in preventing ischemic stroke or TIA." | 5.12 | Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. ( Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE, 2006) |
| "Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a genetically heterogeneous disorder caused by mitochondrial DNA (mtDNA) mutations in the MT-TL1 gene." | 4.12 | Elevated glutamate and decreased glutamine levels in the cerebrospinal fluid of patients with MELAS syndrome. ( Arenas, J; Arranz-Canales, E; Delmiro, A; Domínguez-González, C; González de la Aleja, J; Guerrero-Molina, MP; Martín, MA; Morales-Conejo, M; Morán, M; Ramos-González, A, 2022) |
| " We show that modulation of the eNOS serine 1179 (S1179) phosphorylation site affects vascular reactivity and determines stroke size in vivo." | 3.74 | The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. ( Atochin, DN; Ayata, C; Critchlow, JD; Dantas, AP; Huang, PL; Liu, VW; Looft-Wilson, R; Michel, T; Moskowitz, MA; Murata, T; Salomone, S; Sessa, WC; Shin, HK; Wang, A, 2007) |
| "Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C mutations, being considered unfavourable genetic factors by causing elevated serum homocysteine levels, may be risk factors for cardiovascular disorders, including ischaemic stroke." | 3.73 | [Interactions between the MTHFR C677T and MTHFR A1298C mutations in ischaemic stroke]. ( Fodor, L; Kondacs, A; Melegh, B; Somogyvári, F; Szabó, M; Szolnoki, Z, 2006) |
| "Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2." | 2.69 | Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. ( Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG, 2000) |
| "Sprague-Dawley rats were used in middle cerebral artery occlusion model of stroke." | 1.62 | Post Stroke Safinamide Treatment Attenuates Neurological Damage by Modulating Autophagy and Apoptosis in Experimental Model of Stroke in Rats. ( Dinda, AK; Joshi, B; Reeta, KH; Sharma, U; Singh, D; Wasan, H, 2021) |
| "Safinamide is a newly approved add-on drug to treat Parkinson's disease, and previously studies suggest safinamide could have a potential role on neuroprotection." | 1.56 | The Protective Effect of Safinamide in Ischemic Stroke Mice and a Brain Endothelial Cell Line. ( Kong, S; Sun, R; Wei, G; Xu, T, 2020) |
| "The MELAS has been related to mutation A3243G in most cases, but some other mitochondrial DNA mutations were described in the background of this syndrome as well." | 1.37 | A8344G mutation of the mitochondrial DNA with typical mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome. ( Gál, A; Lukács, T; Molnár, MJ; Reményi, V; Semjén, J; Valikovics, A; Vastagh, I, 2011) |
| "To determine the role of PPAR-gamma2 in genetic susceptibility to ischemic stroke in type 2 diabetes, we genotyped 302 ischemic stroke patients, 283 healthy controls and 141 type 2 diabetic patients without ischemic stroke (diabetes duration >10 years) for PPAR-gamma2 Pro12Ala polymorphism by polymerase chain reaction-restriction fragment length polymorphism methods." | 1.33 | Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. ( Chung, JH; Lee, BC; Lee, HJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Guerrero-Molina, MP | 1 |
| Morales-Conejo, M | 1 |
| Delmiro, A | 1 |
| Morán, M | 1 |
| Domínguez-González, C | 1 |
| Arranz-Canales, E | 1 |
| Ramos-González, A | 1 |
| Arenas, J | 1 |
| Martín, MA | 1 |
| González de la Aleja, J | 1 |
| Sidorov, EV | 1 |
| Rout, M | 1 |
| Xu, C | 1 |
| Jordan, L | 1 |
| Fields, E | 1 |
| Apple, B | 1 |
| Smith, K | 1 |
| Gordon, D | 1 |
| Chainakul, J | 1 |
| Sanghera, DK | 1 |
| Xu, T | 1 |
| Sun, R | 1 |
| Wei, G | 1 |
| Kong, S | 1 |
| Colaco, K | 1 |
| Lee, KA | 1 |
| Akhtari, S | 1 |
| Winer, R | 1 |
| Welsh, P | 1 |
| Sattar, N | 1 |
| McInnes, IB | 1 |
| Chandran, V | 1 |
| Harvey, P | 1 |
| Cook, RJ | 1 |
| Gladman, DD | 1 |
| Piguet, V | 1 |
| Eder, L | 1 |
| Wasan, H | 1 |
| Singh, D | 1 |
| Joshi, B | 1 |
| Sharma, U | 1 |
| Dinda, AK | 1 |
| Reeta, KH | 1 |
| Mosnier, LO | 1 |
| Fernández, JA | 1 |
| Davis, TP | 1 |
| Zlokovic, BV | 1 |
| Griffin, JH | 1 |
| Bian, F | 1 |
| Simon, RP | 1 |
| Li, Y | 1 |
| David, L | 1 |
| Wainwright, J | 1 |
| Hall, CL | 1 |
| Frankel, M | 1 |
| Zhou, A | 1 |
| Markoula, S | 1 |
| Milionis, H | 1 |
| Lazaros, L | 1 |
| Spengos, K | 1 |
| Vassilopoulou, S | 1 |
| Chatzistefanidis, D | 1 |
| Kargiotis, O | 1 |
| Georgiou, I | 1 |
| Kyritsis, AP | 1 |
| Vastagh, I | 1 |
| Gál, A | 1 |
| Reményi, V | 1 |
| Semjén, J | 1 |
| Lukács, T | 1 |
| Valikovics, A | 1 |
| Molnár, MJ | 1 |
| Arpa, A | 1 |
| del Ser, T | 1 |
| Goda, G | 1 |
| Barba, R | 1 |
| Bornstein, B | 1 |
| Pongrácz, E | 1 |
| Tordai, A | 1 |
| Csornai, M | 1 |
| Béla, Z | 1 |
| Nagy, Z | 1 |
| Smith, EE | 1 |
| Cannon, CP | 3 |
| Murphy, S | 1 |
| Feske, SK | 1 |
| Schwamm, LH | 1 |
| Szolnoki, Z | 1 |
| Somogyvári, F | 1 |
| Szabó, M | 1 |
| Kondacs, A | 1 |
| Fodor, L | 1 |
| Melegh, B | 1 |
| Lee, BC | 2 |
| Lee, HJ | 1 |
| Chung, JH | 1 |
| Doo, HK | 1 |
| Ahn, SY | 1 |
| Byun, SH | 1 |
| Kim, SI | 1 |
| Park, HK | 1 |
| Hong, M | 1 |
| Ha, E | 1 |
| Yim, SV | 1 |
| Yin, C | 1 |
| Leem, KH | 1 |
| Ahn, YM | 1 |
| Atochin, DN | 1 |
| Wang, A | 1 |
| Liu, VW | 1 |
| Critchlow, JD | 1 |
| Dantas, AP | 1 |
| Looft-Wilson, R | 1 |
| Murata, T | 1 |
| Salomone, S | 1 |
| Shin, HK | 1 |
| Ayata, C | 1 |
| Moskowitz, MA | 1 |
| Michel, T | 1 |
| Sessa, WC | 1 |
| Huang, PL | 1 |
| McCabe, CH | 1 |
| Wilcox, RG | 1 |
| Langer, A | 1 |
| Caspi, A | 1 |
| Berink, P | 1 |
| Lopez-Sendon, J | 1 |
| Toman, J | 1 |
| Charlesworth, A | 1 |
| Anders, RJ | 1 |
| Alexander, JC | 1 |
| Skene, A | 1 |
| Braunwald, E | 1 |
| Shields, DC | 1 |
| Fitzgerald, AP | 1 |
| O'Neill, PA | 1 |
| Muckian, C | 1 |
| Kenny, D | 1 |
| Moran, B | 1 |
| Byrne, CE | 1 |
| Fitzgerald, DJ | 1 |
4 trials available for alanine and Stroke
| Article | Year |
|---|---|
Nascent proteomes in peripheral blood mononuclear cells as a novel source for biomarker discovery in human stroke.
Topics: Alanine; Biomarkers; Cells, Cultured; Cluster Analysis; Female; Humans; Leukocytes, Mononuclear; Mal | 2014 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-U | 2006 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Femal | 2000 |
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Topics: Alanine; Coronary Disease; Genotype; Glycoproteins; Hemorrhage; Humans; Myocardial Infarction; Myoca | 2002 |
14 other studies available for alanine and Stroke
| Article | Year |
|---|---|
Elevated glutamate and decreased glutamine levels in the cerebrospinal fluid of patients with MELAS syndrome.
Topics: Adult; Alanine; Case-Control Studies; DNA, Mitochondrial; Female; Glutamic Acid; Glutamine; Humans; | 2022 |
Difference in acute and chronic stage ischemic stroke metabolic markers with controls.
Topics: Alanine; Biomarkers; Humans; Ischemic Stroke; Longitudinal Studies; Pilot Projects; Stroke | 2023 |
The Protective Effect of Safinamide in Ischemic Stroke Mice and a Brain Endothelial Cell Line.
Topics: Alanine; Animals; Benzylamines; Blood-Brain Barrier; Brain; Brain Ischemia; Cells, Cultured; Endothe | 2020 |
Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis.
Topics: Adult; Alanine; Angina Pectoris; Apolipoproteins B; Arthritis, Psoriatic; Cardiovascular Diseases; C | 2021 |
Post Stroke Safinamide Treatment Attenuates Neurological Damage by Modulating Autophagy and Apoptosis in Experimental Model of Stroke in Rats.
Topics: Alanine; Animals; Apoptosis; Autophagy; Benzylamines; Brain; Cytokines; Disease Models, Animal; Infa | 2021 |
Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity.
Topics: Alanine; Anticoagulants; Blood Coagulation; Dose-Response Relationship, Drug; Genetic Variation; Hum | 2013 |
Associations of ESR2 AluI (G/A) polymorphism with ischemic stroke in Caucasians.
Topics: Aged; Aged, 80 and over; Alanine; Alu Elements; Brain Ischemia; Estrogen Receptor beta; Female; Gene | 2012 |
A8344G mutation of the mitochondrial DNA with typical mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome.
Topics: Acidosis, Lactic; Adult; Alanine; Brain Ischemia; DNA, Mitochondrial; Glycine; Humans; Male; MELAS S | 2011 |
Apolipoprotein E, angiotensin-converting enzyme and alpha-1-antichymotrypsin genotypes are not associated with post-stroke dementia.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Alleles; alpha 1-Antitrypsin; Apolipoproteins E; Cysteine; | 2003 |
[Significance of Factor V gene A506G mutation (Leiden) in the pathogenesis of ischemic stroke].
Topics: Adult; Age of Onset; Alanine; Brain Ischemia; DNA Mutational Analysis; Factor V; Female; Genetic Pre | 2003 |
[Interactions between the MTHFR C677T and MTHFR A1298C mutations in ischaemic stroke].
Topics: Adult; Aged; Alanine; Alleles; Brain Ischemia; Cysteine; Female; Humans; Male; Methylenetetrahydrofo | 2006 |
Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes.
Topics: Aged; Alanine; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genetic Predisposition to Disease; | 2006 |
Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism is associated with the susceptibility to ischemic stroke in Taeeumin classified by Sasang medicine.
Topics: Aged; Alanine; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Male; Me | 2007 |
The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo.
Topics: Alanine; Animals; Aspartic Acid; Brain Ischemia; Cerebral Arteries; Disease Models, Animal; Gene Exp | 2007 |